Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?
Zentalis Pharmaceuticals announced the FDA's partial clinical hold on azenosertib studies due to recent patient deaths.
CEL-SCI Presents Head & Neck Cancer Data At IDDST Annual Congress In Budapest: Risk Of Death Cut In Half For Patients Treated With Multikine In The Target Population
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors73% survival for Multikine vs 45% in the control arm at 5
Takeda To Present Long-Term Data From Phase 3 ADVANCE-CIDP 3 Clinical Trial Of HYQVIA In Patients With Chronic Inflammatory Demyelinating Polyneuropathy At PNS Annual Meeting
Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDPADVANCE Clinical Program Reflects Takeda's
FDA Approves Merck’s Pneumococcal Vaccine As First Shot Designed For Adults
The FDA has approved Merck's Capvaxive, the first pneumococcal conjugate vaccine for adults, protecting against 21 strains of bacteria. Additionally, Merck's Keytruda received FDA approval for advanced endometrial carcinoma.
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With NRAS-Mutant Melanoma
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to dateFavorable mOS and mPFS demonstrated in pooled
Taysha Gene Therapies Announced Longer-term Clinical Data From Ongoing REVEAL Phase 1/2 Adolescent And Adult Trial And Initial Clinical Data From REVEAL Phase 1/2 Pediatric Trial Of TSHA-102 In Rett Syndrome
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen
Vaxart Stock Is Moving Higher After The Bell: What’s Going On?
Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.
Kyverna Therapeutics Presents First-In-Disease Use Of KYV-101 In Patient With Severe Stiff-Person Syndrome Published In Proceedings Of The National Academy Of Sciences
Patient received KYV-101, a fully human anti-CD19 CAR T-cell product candidate, as part of a named-patient treatment option after failure to respond to conventional therapiesSignificant improvement in walking distance
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech partner MediLink Therapeutics faces a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202 for advanced non-small cell lung cancer and HR+/HER2-negative breast cancer.
Pfizer’s COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims
Kansas has filed a lawsuit against Pfizer, Inc., alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine, resulting in consumer protection violations and record revenues.